**Karen V. Gregory,**

*Secretary.*

[FR Doc. 2010–4202 Filed 3–1–10; 8:45 am]

**BILLING CODE 6730–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. FDA–2010–N–0001]**

### Advisory Committee Information Hotline

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that we have revised the Advisory Committee Information Hotline (the hotline). The hotline provides the public with access to the most current information available on FDA advisory committee meetings. This notice supersedes all previously published announcements of FDA's Advisory Committee Information Hotline.

**FOR FURTHER INFORMATION CONTACT:** Michael F. Ortwerth, Director, Advisory Committee Oversight and Management Staff (HF–4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1220.

**SUPPLEMENTARY INFORMATION:** The Advisory Committee Information Hotline can be accessed by dialing 1–800–741–8138 or 301–443–0572. The advisory committee meeting information and information updates can also be accessed via FDA's Advisory Committee Internet site at *http://www.fda.gov/AdvisoryCommittees/default.htm*.

Each advisory committee is assigned a 10-digit number. This 10-digit number will appear in each individual notice of meeting. The public can obtain information about a particular advisory committee meeting by using the committee's 10-digit number. Information on the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made. The following is a list of each advisory committee's 10-digit number to be used when accessing the hotline. The list has been updated to add the newly established advisory committee in the Center for Tobacco called the Tobacco Products Scientific Advisory Committee.

| Advisory Committee | 10-Digit Access Number |
|---|---|
| OFFICE OF THE COMMISSIONER | |
| Pediatric Advisory Committee | 8732310001 |
| Risk Communication Advisory Committee | 8732112560 |
| Science Board to the FDA | 3014512603 |
| CENTER FOR BIOLOGICS EVALUATION AND RESEARCH | |
| Allergenic Products Advisory Committee | 3014512388 |
| Blood Products Advisory Committee | 3014519516 |
| Cellular, Tissue & Gene Therapies Advisory Committee | 3014512389 |
| Transmissible Spongiform Encephalopathies Advisory Committee | 3014512392 |
| Vaccines and Related Biological Products Advisory Committee | 3014512391 |
| CENTER FOR DRUG EVALUATION AND RESEARCH | |
| Anesthetic and Life Support Drugs Advisory Committee | 3014512529 |
| Anti-Infective Drugs Advisory Committee | 3014512530 |
| Antiviral Drugs Advisory Committee | 3014512531 |
| Arthritis Advisory Committee | 3014512532 |
| Cardiovascular and Renal Drugs Advisory Committee | 3014512533 |
| Dermatologic and Ophthalmic Drugs Advisory Committee | 3014512534 |
| Drug Safety and Risk Management Advisory Committee | 3014512535 |
| Endocrinologic and Metabolic Drugs Advisory Committee | 3014512536 |
| Gastrointestinal Drugs Advisory Committee | 3014512538 |
| Nonprescription Drugs Advisory Committee | 3014512541 |
| Oncologic Drugs Advisory Committee | 3014512542 |
| Peripheral and Central Nervous System Drugs Advisory Committee | 3014512543 |
| Pharmaceutical Science & Clinical Pharmacology, Advisory Committee for (formerly Advisory Committee for Pharmaceutical Science) | 3014512539 |

| Advisory Committee | 10-Digit Access Number |
|---|---|
| Psychopharmacologic Drugs Advisory Committee | 3014512544 |
| Pulmonary-Allergy Drugs Advisory Committee | 3014512545 |
| Reproductive Health Drugs, Advisory Committee for | 3014512537 |
| CENTER FOR FOOD SAFETY AND APPLIED NUTRITION | |
| Food Advisory Committee | 3014510564 |
| CENTER FOR DEVICES AND RADIOLOGICAL HEALTH | |
| Device Good Manufacturing Practice Advisory Committee | 3014512398 |
| Medical Devices Advisory Committee comprised of 18 panels) | |
| Anesthesiology and Respiratory Therapy Devices Panel | 3014512624 |
| Circulatory System Devices Panel | 3014512625 |
| Clinical Chemistry and Clinical Toxicology Devices Panel | 3014512514 |
| Dental Products Panel | 3014512518 |
| Ear, Nose, and Throat Devices Panel | 3014512522 |
| Gastroenterology-Urology Devices Panel | 3014512523 |
| General and Plastic Surgery Devices Panel | 3014512519 |
| General Hospital and Personal Use Devices Panel | 3014512520 |
| Hematology and Pathology Devices Panel | 3014512515 |
| Immunology Devices Panel | 3014512516 |
| Medical Devices Dispute Resolution Panel | 3014510232 |
| Microbiology Devices Panel | 3014512517 |
| Molecular and Clinical Genetics Panel | 3014510231 |
| Neurological Devices Panel | 3014512513 |
| Obstetrics-Gynecology Devices | 3014512524 |
| Ophthalmic Devices Panel | 3014512396 |
| Orthopaedic and Rehabilitation Devices Panel | 3014512521 |
| Radiological Devices Panel | 3014512526 |
| National Mammography Quality Assurance Advisory Committee | 3014512397 |
| Technical Electronic Product Radiation Safety Standards Committee | 3014512399 |
| CENTER FOR TOBACCO | |
| Tobacco Products Scientific Advisory Committee | 8732110002 |
| CENTER FOR VETERINARY MEDICINE | |
| Veterinary Medicine Advisory Committee | 3014512548 |
| NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR) | |
| Science Advisory Board to NCTR | 3014512559 |

The hotline will provide the most recent information available on upcoming advisory committee meetings, guidance for making an oral presentation during the open public hearing portion of a meeting, and procedures on obtaining copies of transcripts of advisory committee meetings. Because the hotline will communicate the most current information available about any particular advisory committee meeting, this system will provide interested parties with timely and equal access to such information. The hotline should

also conserve agency resources by reducing the current volume of inquiries individual FDA offices and employees must handle concerning advisory committee schedules and procedures.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: February 24, 2010.

**Joanne Less,**

*Acting Associate Commissioner for Special Medical Programs.*

[FR Doc. 2010–4258 Filed 3–1–10; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### Submission for OMB Review; Comment Request; Reinstatement of OMB No. 0925–0601/exp. 02/28/2010, Request for Human Embryonic Stem Cell Line To Be Approved for Use in NIH Funded Research

**SUMMARY:** Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a reinstatement of approval of the information collection listed below. This proposed information collection was previously published in the **Federal Register** on September 25, 2009, page 48973 and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection unless it displays a currently valid OMB control number.

*Proposed Collection: Title:* Request for Human Embryonic Stem Cell Line to be Approved for Use in NIH Funded Research. *Type of Information Collection Request:* Revision, OMB 0925–0601, Expiration Date 02/28/2010, Form Number: NIH 2890. *Need and Use of Information Collection:* The form is used by applicants to request that human embryonic stem cell lines be approved for use in NIH funded research. *Frequency of response:* Applicants may submit applications at any time; this request is a one-time submission. *Affected Public:* Business or other for-profit; Not-for-profit institutions; Federal Government; and State, Local or Tribal Government. *Type of Respondents:* Adult scientific professionals. The annual reporting burden is as follows: *Estimated Number of Respondents:* 160,135; *Estimated Number of Responses per Respondent:* 1; *Average Burden Hours per Response:* 14; and *Estimated Total Annual Burden Hours Requested:* 2,251,500. The estimated annualized cost to respondents is $78,802,500.

*Request for Comments:* Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

*Direct Comments to OMB:* Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, *OIRA_submission@omb.eop.gov* or by fax to 202–395–6974, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Ms. Mikia Currie, Division of Grants Policy, Office of Policy for Extramural Research Administration, NIH, Rockledge 1 Building, Room 3505, 6705 Rockledge Drive, Bethesda, MD 20892–7974, or call non-toll-free number (301) 435–0941, or E-mail your request, including your address to: *curriem@od.nih.gov.*

*Comments Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

Dated: February 25, 2010.

**Mikia Currie,**

*Office of Policy for Extramural Research Administration, OD, NIH.*

[FR Doc. 2010–4301 Filed 3–1–10; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

### Submission for OMB Review; Comment Request

*Title:* Evaluation of Adolescent Pregnancy Prevention Approaches—Baseline Data Collection.

*OMB No.:* ICRAS: 0970–0360.

*Description:* The Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is proposing a data collection activity as part of the Evaluation of Adolescent Pregnancy Prevention Approaches (PPA). PPA is being undertaken to expand available evidence on effective ways to reduce teen pregnancy. The evaluation will document and test a range of pregnancy prevention approaches in up to eight program sites. Program impacts will be estimated using a random assignment design, involving random assignment at the school, individual, or other level, depending on the program setting. The findings of the evaluation will be of interest to the general public, to policy-makers, and to organizations interested in teen pregnancy prevention.

This proposed information collection activity focuses on collecting baseline data from a self-administered questionnaire which will be used to perform meaningful analysis to determine significant program effects. Through a survey instrument, respondents will be asked to answer carefully selected questions about demographics and risk and protective factors related to teen pregnancy. As appropriate to each program being evaluated, youth records, performance, and program participation data will also be collected.

*Respondents:* The data will be collected through private, self-administered questionnaires completed by study participants, *i.e.* adolescents assigned to a select school or community teen pregnancy prevention program or a control group. Surveys will be distributed and collected by trained professional staff. Youth school records, performance, and program participation data will also be collected from participating schools and organizations, as appropriate to the site.